Literature DB >> 17950950

Insulin administration may trigger pancreatic beta-cell destruction in patients with type 2 diabetes.

Mai Nakamura1, Wataru Nishida, Yuya Yamada, Daisuke Chujo, Yuji Watanabe, Akihisa Imagawa, Toshiaki Hanafusa, Eiji Kawasaki, Hiroshi Onuma, Haruhiko Osawa, Hideichi Makino.   

Abstract

Insulin administration causes various types of immune response to insulin. However, there have been no reports that insulin administration triggers pancreatic beta-cell destruction in diabetic patients. We evaluated three patients who had suffered from type 2 diabetes or impaired glucose tolerance for 5-30 years. After an episode of diabetic mononeuropathy or poor glycemic control, they started human insulin therapy. All the patients' serum or urinary C-peptide levels were preserved before insulin therapy, whereas within a few months they rapidly declined to below detection limits. A high titer of insulin antibody was detected at or after the development of insulin deficiency. Shortly after the initiation of insulin therapy, two of the patients developed an insulin allergy. Autoantibodies to GAD65 or IA-2 were negative throughout the clinical course in two cases, but transiently positive in one case. In a histological examination of pancreas tissue obtained by a pancreatic biopsy in one case, mononuclear cell infiltration into the islets was observed. They all had a type 1 diabetes high-risk HLA class II haplotype in Japanese, and class I alleles of the insulin gene VNTR. The above findings suggest that insulin administration may have triggered pancreatic beta-cell destruction in these patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17950950     DOI: 10.1016/j.diabres.2007.08.031

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  4 in total

1.  Class I MHC Polymorphisms Associated with Type 2 Diabetes in the Mexican Population.

Authors:  Paola Mendoza-Ramírez; Mildred Alejandra López-Olaiz; Adriana Lizeth Morales-Fernández; María Isabel Flores-Echiveste; Antonio de Jesus Casillas-Navarro; Marco Andrés Pérez-Rodríguez; Felipe de Jesús Orozco-Luna; Celso Cortés-Romero; Laura Yareni Zuñiga; María Guadalupe Sanchez Parada; Luis Daniel Hernandez-Ortega; Arieh Roldán Mercado-Sesma; Raúl C Baptista-Rosas
Journal:  Genes (Basel)       Date:  2022-04-27       Impact factor: 4.141

2.  Variants in the BACH2 and CLEC16A gene might be associated with susceptibility to insulin-triggered type 1 diabetes.

Authors:  Hiroshi Onuma; Ryoichi Kawamura; Yasuharu Tabara; Masakatsu Yamashita; Jun Ohashi; Eiji Kawasaki; Akihisa Imagawa; Yuya Yamada; Daisuke Chujo; Kenji Takahashi; Tadashi Suehiro; Yasunori Takata; Haruhiko Osawa; Hideichi Makino
Journal:  J Diabetes Investig       Date:  2019-05-14       Impact factor: 4.232

3.  Etiopathogenesis of insulin autoimmunity.

Authors:  Norio Kanatsuna; George K Papadopoulos; Antonis K Moustakas; Ake Lenmark
Journal:  Anat Res Int       Date:  2012-02-22

4.  Recurrent Hypoglycemia Due to a High Titer of Insulin Antibody in Response to Exogenous Insulin Administration in Two Cases of Type 1 Diabetes.

Authors:  Ryoichi Kawamura; Satoshi Miyao; Hiroshi Onuma; Yasuko Uchigata; Eiji Kawasaki; Jun Ohashi; Sanshiro Shiraishi; Wataru Nishida; Maki Yokomoto-Umakoshi; Yasunori Takata; Haruhiko Osawa; Hideichi Makino
Journal:  Intern Med       Date:  2021-08-31       Impact factor: 1.271

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.